November 22nd 2024
With FDA's clearance, Kedrion can manufacture Ryplazim (plasminogen, human-tvmh), the first and only FDA-approved therapy for treating PLGD-1, at its Bolognana, Italy, site.
November 21st 2024
Chr. Hansen, Lonza Joint Venture Gets Anti-Trust Nod to Manufacture Live Biotherapeutics
September 3rd 2019The joint venture, named BacThera, will operate out of headquarters in Basel, Switzerland and will serve pre-clinical to Phase II projects, with the ability to expand to Phase III and commercial manufacturing in the future.